Helus Pharma Appoints Former Pfizer CMO Dr. Freda Lewis-Hall to Board and Scientific Advisory Chair

summarizeSummary

Helus Pharma, operating as Cybin Inc., has appointed Dr. Freda Lewis-Hall, former Pfizer Chief Medical Officer, to its Board of Directors and as Chair of its Scientific Advisory Committee, significantly bolstering its clinical and regulatory expertise.

check_boxKey Events

• High-Profile Board Appointment

  Dr. Freda Lewis-Hall, a distinguished physician and biopharmaceutical executive, has been appointed to Helus Pharma's Board of Directors.

• Scientific Advisory Committee Leadership

  Dr. Lewis-Hall will also serve as Chair of the Company's Scientific Advisory Committee, guiding clinical development and regulatory strategy.

• Extensive Industry Experience

  Her background includes over a decade as Executive Vice President and Chief Medical Officer at Pfizer, as well as senior leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, and Eli Lilly and Company.

• Strategic Enhancement for Clinical-Stage Company

  This appointment is crucial for a clinical-stage pharmaceutical company like Helus Pharma, providing invaluable expertise in advancing its novel serotonergic agonist (NSA) portfolio for mental health conditions.

auto_awesomeAnalysis

The appointment of Dr. Freda Lewis-Hall, a former Chief Medical Officer at Pfizer and a seasoned biopharmaceutical executive, to both the Board of Directors and as Chair of the Scientific Advisory Committee is a highly significant development for Helus Pharma (Cybin Inc.). Her extensive experience in clinical development, regulatory engagement, and global commercialization, particularly in mental health, provides a substantial boost to the company's credibility and strategic capabilities. This move follows recent positive Phase 2a clinical trial results and a substantial $175 million financing round, indicating a strategic focus on strengthening leadership to advance its novel serotonergic agonist (NSA) pipeline and execute on its growth plans.